Preview Mode Links will not work in preview mode

Nov 27, 2018

Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours – a major shift in oncology treatment.

Yet even this groundbreaking therapy has limitations, such as when patients already immuno-depressed from a first-line treatment do not have...


Nov 20, 2018

The staggering clinical trial failure rate of experimental drugs indicates that despite huge investments in novel technologies over the years, productivity gains in the pharmaceutical industry remained elusive. It is therefore generally agreed that the current biopharma model is unsustainable and disruptive approaches...


Nov 16, 2018

The staggering failure rate of experimental drugs in clinical trials indicates that despite huge investments in novel technologies, productivity gains in the pharmaceutical industry remain elusive. The pharmaceutical industry is facing a serious innovation deficit.

The current biopharma model is therefore unsustainable...


Nov 13, 2018

The staggering failure rate of experimental drugs in clinical trials indicates that despite huge investments in novel technologies, productivity gains in the pharmaceutical industry remain elusive. The pharmaceutical industry is facing a serious innovation deficit.

The current biopharma model is therefore unsustainable...


Nov 6, 2018

There is a new phenomenon sweeping the globe (or at least sweeping the imagination of people around the globe). It is the human gut microbiome and the role it may play in the future of human health.

Recent reports have indicated that the human gut microbiome may be implicated in a whole variety of health conditions such...